Alnylam Set To Bring 3rd Program Into Clinic; Continue Progress Of Other Two
Executive Summary
Alnylam plans to file an IND at FDA by the end of this year for a drug candidate to treat transthyretin-mediated amyloidosis (ATTR), with a goal of beginning Phase I study early next year, the biotech reported during an investor research and development presentation Nov. 12 (see chart: "1Alnylam's Aggressive Business Development Program Has Yielded Results")
You may also be interested in...
Alnylam CEO John Maraganore: An Interview With "The Pink Sheet" DAILY (Part 2 of 2)
CEO of the RNAi pioneer talks about his company's "5x15" product development strategy and his hopes not to have to access the capital markets anytime soon.
Would AstraZeneca Be Better Off If Rezield Had Gotten A Harsher FDA Letter?
AstraZeneca subsidiary MedImmune received a "complete response" letter from FDA for its RSV drug motavizumab that did not request additional clinical data, but after an unfavorable advisory committee a year and a half later, the company is looking at the prospect of having to do another trial anyway
Would AstraZeneca Be Better Off If Rezield Had Gotten A Harsher FDA Letter?
AstraZeneca subsidiary MedImmune received a "complete response" letter from FDA for its RSV drug motavizumab that did not request additional clinical data, but after an unfavorable advisory committee a year and a half later, the company is looking at the prospect of having to do another trial anyway